Endo in another below-the-belt acquisition

Share this article:
Endo Pharmaceuticals announced plans to acquire American Medical Systems, a Minnesota maker of pelvic health products and devices.

The $2.9 billion deal is the latest in a string of acquisitions for Chadds Ford, PA-based Endo, a specialty firm best known for its pain portfolio. Endo acquired generics-maker Qualitest in December and urology specialty HealthTronics last July.

American Medical Systems, which makes products for male and female incontinence, erectile dysfunction, prostate disorders, urethral strictures and other pelvic floor conditions including prolapse, reported a 4.4% rise in revenue for 2010 over 2009 to $542.3 million. That made it about a quarter the size of Endo, which reported revenues up 17% to $1.7 billion for 2010 and has forecast 2011 sales of between $2.35 billion and $2.45 billion. The combined company will have around 4,000 employees and revenues of around $3 billion, said Endo.

Endo president and CEO Dave Holveck said in a statement: “Through the acquisition of AMS, we will gain scale in devices and services, and will be positioned as a leading provider of healthcare solutions in the field of pelvic health, with a full spectrum of product offerings ranging from pharmaceuticals to medical devices.”

While Endo's pain portfolio remains its bread and butter, the company has been building a respectable franchise in urology and sexual health, most recently with the FDA approval in December of Fortesta, a topical gel for low testosterone that is being launched with 500 reps – around two-thirds of Endo's pre-merger sales force.  
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?